Difference between revisions of "Naibogllu"
(Imported from Wikispaces) |
|||
| Line 1: | Line 1: | ||
| − | '''<span style="font-size: | + | |
| − | + | <span style="line-height:normal">'''<span style="font-size:18.0pt"><span style="font-family:" times="" new="" roman",serif"="">No additional improvement with the addition of intra-tympanic steroid to systemic steroid & hyperbaric oxygen treatment for sudden hearing loss</span></span>'''</span> | |
| − | + | ||
| + | <span style="line-height:normal">'''<span style="font-size:14.0pt"><span style="font-family:" times="" new="" roman",serif"="">Clinical Bottom Line:</span></span>'''</span> | ||
| + | |||
| + | {| class="Table" style="border:undefined" | ||
|- | |- | ||
| + | | | ||
| + | <span style="line-height:normal"><span style="font-size:14.0pt"><span style="font-family:" times="" new="" roman",serif"="">1. Overall both groups improved in terms of pure tone average measurement by the end of the study but there was no difference between groups.<br/> 2. In the subgroup of patients with profound hearing loss, those in the intratympanic steroid group may do better.</span></span></span> | ||
| + | |||
|} | |} | ||
| − | + | ---- | |
| − | <span style=" | + | <span style="line-height:normal">'''<span style="font-size:14.5pt"><span style="font-family:" times="" new="" roman",serif"="">Citation/s:</span></span>'''<span style="font-size:14.5pt"><span style="font-family:" times="" new="" roman",serif"="">1. Naibogllu B, Külekçi S, Sürmeli M, Verim A, Ertugay CK, Ýhvan O, Seneldir L, SZ Toros. Efficacy of multimodality approach to sudden hearing loss. The Turkish Journal of Ear, Nose and Throat. 2015; 25(2):77-81.</span></span></span> |
| − | <span style="font-size: | ||
| − | <span style="font-size: | + | <span style="line-height:normal">'''<span style="font-size:14.5pt"><span style="font-family:" times="" new="" roman",serif"="">Lead author's name and email:</span></span>'''<span style="font-size:14.5pt"><span style="font-family:" times="" new="" roman",serif"="">Dr Onder Yhvan, onderihvan@yahoo.com '''Three-part Clinical Question:''' Does the addition of intra-tympanic steroid to systemic steroid & hyperbaric oxygen treatment improve the outcome of sudden hearing loss?</span></span></span> |
| − | + | <span style="line-height:normal">'''<span style="font-size:14.5pt"><span style="font-family:" times="" new="" roman",serif"="">Search Terms:</span></span>'''<span style="font-size:14.5pt"><span style="font-family:" times="" new="" roman",serif"="">Hearing loss, steroid, intratympanic</span></span></span> | |
| − | <span style=" | + | <span style="line-height:normal">'''<span style="font-size:14.5pt"><span style="font-family:" times="" new="" roman",serif"="">The Study:</span></span>'''<span style="font-size:14.5pt"><span style="font-family:" times="" new="" roman",serif"="">Non-blinded randomised controlled trial with intention-to-treat.</span></span></span> |
| − | <span style="font- | ||
| − | <span style="font-size: | ||
| − | + | <span style="line-height:normal">'''<span style="font-size:14.5pt"><span style="font-family:" times="" new="" roman",serif"="">The Study Patients:</span></span>'''<span style="font-size:14.5pt"><span style="font-family:" times="" new="" roman",serif"="">Patients presenting within 72 hours idiopathic hearing loss of at least 30dB over 3 contiguous test frequencies over 3 days.</span></span></span> | |
| − | + | ||
| − | + | <span style="line-height:normal">'''<span style="font-size:14.5pt"><span style="font-family:" times="" new="" roman",serif"="">Control group (N = 20; 20 analysed):</span></span>'''<span style="font-size:14.5pt"><span style="font-family:" times="" new="" roman",serif"="">Oral prednisone starting at 1mg/kg tapering over 14 days plus hyperbaric oxygen therapy (2.5atm for 90 minutes) once daily for 10 days</span></span></span> | |
| + | |||
| + | <span style="line-height:normal">'''<span style="font-size:14.5pt"><span style="font-family:" times="" new="" roman",serif"="">Experimental group (N = 38; 38 analysed):</span></span>'''<span style="font-size:14.5pt"><span style="font-family:" times="" new="" roman",serif"="">As above plus 3 intratympanic doses of 40mg prednisone commencing at the start of hyperbaric treatment and 3 days apart for subsequent doses.</span></span></span> | ||
| + | |||
| + | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">The Evidence:</span></span>'''</span> | ||
| + | |||
| + | {| class="Table" style="border:solid windowtext 1.0pt" | ||
|- | |- | ||
| − | | < | + | | style="border: 1pt solid windowtext; width: 155px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Outcome</span></span>'''</span></p> |
| + | | style="border: 1pt solid windowtext; width: 105px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Time to Outcome</span></span>'''</span></p> | ||
| + | | style="border: 1pt solid windowtext; width: 80px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Control group</span></span>'''</span></p> | ||
| + | | style="border: 1pt solid windowtext; width: 92px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Intra-tymp. group</span></span>'''</span></p> | ||
| + | | style="border: 1pt solid windowtext; width: 125px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Relative risk reduction</span></span>'''</span></p> | ||
| + | | style="border: 1pt solid windowtext; width: 127px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Absolute risk reduction</span></span>'''</span></p> | ||
| + | | style="border: 1pt solid windowtext; width: 140px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">NNT</span></span>'''</span></p> | ||
|- | |- | ||
| − | | | + | | rowspan="2" style="border: 1pt solid windowtext; width: 155px;" | |
| + | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Complete recovery by Siegel's Criteria</span></span>'''</span> | ||
| + | |||
| + | | style="border: 1pt solid windowtext; width: 105px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">1 month</span></span></span></p> | ||
| + | | style="border: 1pt solid windowtext; width: 80px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">0.30</span></span></span></p> | ||
| + | | style="border: 1pt solid windowtext; width: 92px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">0.29</span></span></span></p> | ||
| + | | style="border: 1pt solid windowtext; width: 125px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">4%</span></span></span></p> | ||
| + | | style="border: 1pt solid windowtext; width: 127px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">0.01</span></span></span></p> | ||
| + | | style="border: 1pt solid windowtext; width: 140px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">91</span></span></span></p> | ||
|- | |- | ||
| + | | colspan="3" style="border: 1pt solid windowtext; width: 291px;" | <p align="right" style="margin-bottom:.0001pt; text-align:right; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">95% CIs:</span></span></span></p> | ||
| + | | style="border: 1pt solid windowtext; width: 125px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">-79% to 86%</span></span></span></p> | ||
| + | | style="border: 1pt solid windowtext; width: 127px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">-0.24 to 0.26</span></span></span></p> | ||
| + | | style="border: 1pt solid windowtext; width: 140px;" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">NNT 4 to INF;<br/> NNH 4 to INF</span></span></span></p> | ||
|} | |} | ||
| − | |||
| − | + | | |
| − | <span style="font-size: | + | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Comments:</span></span>'''</span> |
| − | <span style="font-size: | + | <span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">1. This study is not a trial of HBOT but rather a trial of intra-tympanic steroid</span></span></span> |
| − | <span style="font-size: | + | <span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">2. Methods do not describe the randomisation process or if blinded and small sample groups limit the generalisation of the study</span></span></span> |
| − | <span style="font-size: | + | <span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">4. Post-hoc subgroup analysis suggests the profoundly deaf subgroup had better recover with the addition of intra-tympanic steroids.</span></span></span> |
| − | <span style="font-size: | + | <span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">5. All patients had an MRI to exclude space occupying lesions.</span></span></span> |
| − | <span style=" | + | <span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">6. Siegel’s criteria define complete recovery as an improvement of at least 25dB</span></span></span> |
| − | <span style="font- | ||
| − | <span style=" | + | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Appraised by:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Dr Katherine Witheridge Department of Diving and Hyperbaric Medicine Prince of Wales Hospital ; Friday, 4 May 2018: katherine.witheridge@health.nsw.gov.au</span></span></span> |
| − | + | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Kill or Update By:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">June 2022</span></span></span> | |
| + | [[File:Sumhorsa.gif|center|Sumhorsa.gif]] | ||
| − | <span style="display: block; text-align: center;"><span style="font-size: 29.9px;">[[Audiovestibular | + | <span style="display: block; text-align: center;"><span style="font-size: 29.9px;">[[Audiovestibular|BACK]]</span></span> |
Latest revision as of 01:53, 30 September 2021
No additional improvement with the addition of intra-tympanic steroid to systemic steroid & hyperbaric oxygen treatment for sudden hearing loss
Clinical Bottom Line:
|
1. Overall both groups improved in terms of pure tone average measurement by the end of the study but there was no difference between groups. |
Citation/s:1. Naibogllu B, Külekçi S, Sürmeli M, Verim A, Ertugay CK, Ýhvan O, Seneldir L, SZ Toros. Efficacy of multimodality approach to sudden hearing loss. The Turkish Journal of Ear, Nose and Throat. 2015; 25(2):77-81.
Lead author's name and email:Dr Onder Yhvan, onderihvan@yahoo.com Three-part Clinical Question: Does the addition of intra-tympanic steroid to systemic steroid & hyperbaric oxygen treatment improve the outcome of sudden hearing loss?
Search Terms:Hearing loss, steroid, intratympanic
The Study:Non-blinded randomised controlled trial with intention-to-treat.
The Study Patients:Patients presenting within 72 hours idiopathic hearing loss of at least 30dB over 3 contiguous test frequencies over 3 days.
Control group (N = 20; 20 analysed):Oral prednisone starting at 1mg/kg tapering over 14 days plus hyperbaric oxygen therapy (2.5atm for 90 minutes) once daily for 10 days
Experimental group (N = 38; 38 analysed):As above plus 3 intratympanic doses of 40mg prednisone commencing at the start of hyperbaric treatment and 3 days apart for subsequent doses.
The Evidence:
Outcome |
Time to Outcome |
Control group |
Intra-tymp. group |
Relative risk reduction |
Absolute risk reduction |
NNT |
|
Complete recovery by Siegel's Criteria |
1 month |
0.30 |
0.29 |
4% |
0.01 |
91 |
95% CIs: |
-79% to 86% |
-0.24 to 0.26 |
NNT 4 to INF; | |||
Comments:
1. This study is not a trial of HBOT but rather a trial of intra-tympanic steroid
2. Methods do not describe the randomisation process or if blinded and small sample groups limit the generalisation of the study
4. Post-hoc subgroup analysis suggests the profoundly deaf subgroup had better recover with the addition of intra-tympanic steroids.
5. All patients had an MRI to exclude space occupying lesions.
6. Siegel’s criteria define complete recovery as an improvement of at least 25dB
Appraised by:Dr Katherine Witheridge Department of Diving and Hyperbaric Medicine Prince of Wales Hospital ; Friday, 4 May 2018: katherine.witheridge@health.nsw.gov.au
Kill or Update By:June 2022